Sonnet BioTherapeutics has received a patent from the European Patent Office (EPO) for its fully human albumin binding (FHAB) technology.

Sonnet's F H AB platform consists of a single, fully human construct of a F H AB antibody fragment that has high affinity to bind to human albumin. The platform provides an off-the-shelf lock and load ...

SalubrisBio shared interim results from an ongoing Phase II heart failure trial examining its recombinant antibody fusion protein, JK07.

SEOUL, South Korea, Jan. 17, 2025 /PRNewswire/ -- LOTTE BIOLOGICS (CEO James Park) announced on January 16 that it had ...

Lotte Biologics CEO James Park aims to secure ADC orders at U.S. plant this year Lotte Biologics new leadership seeks to ...

Dual blocking SHP2 and FGFR2 can not only promote the targeted tumor-killing effects and overcome FGFR2 inhibitor resistance caused by feedback activation, but also activate T cell-mediated anti-tumor ...

Construction output estimates are monthly estimates of the amount of output chargeable to customers for building and civil engineering work done in the relevant period, excluding Value Added Tax (VAT) ...

Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising the anti-A proliferation-inducing ligand (APRIL) monoclonal antibody, CLYM116 ...

The approval of the ITA is an important step towards getting the Multiplo ® Complete Syphilis (TP/nTP) Antibody Test licensed and into the Canadian market. MedMira offers the only commercially ...

COVID-like virus scare in China: The sudden rise in infections in China has sparked concerns about another virus outbreak after the Coronavirus. Authorities have detected some viruses that might ...

Antibodies that bind to a previously untargeted portion of the malaria parasite could lead to new monoclonal antibody treatments and vaccines for malaria. A novel class of antibodies that binds to ...